25 XP   0   0   10

Scpharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Scpharmaceuticals together

PenkeI guess you are interested in Scpharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Scpharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Scpharmaceuticals Inc

I send you an email if I find something interesting about Scpharmaceuticals Inc.

Quick analysis of Scpharmaceuticals (30 sec.)










What can you expect buying and holding a share of Scpharmaceuticals? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
3.3%

What is your share worth?

Current worth
$0.96
Expected worth in 1 year
$-0.09
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-1.05
Return On Investment
-23.3%

For what price can you sell your share?

Current Price per Share
$4.51
Expected price per share
$3.68 - $4.74
How sure are you?
50%

1. Valuation of Scpharmaceuticals (5 min.)




Live pricePrice per Share (EOD)

$4.51

Intrinsic Value Per Share

$-14.55 - $-17.05

Total Value Per Share

$-13.59 - $-16.09

2. Growth of Scpharmaceuticals (5 min.)




Is Scpharmaceuticals growing?

Current yearPrevious yearGrowGrow %
How rich?$37.2m$48.3m$8m14.3%

How much money is Scpharmaceuticals making?

Current yearPrevious yearGrowGrow %
Making money-$14.1m-$9.5m-$4.5m-32.1%
Net Profit Margin-531.1%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Scpharmaceuticals (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#516 / 1016

Most Revenue
#391 / 1016

Most Profit
#618 / 1016

Most Efficient
#755 / 1016

What can you expect buying and holding a share of Scpharmaceuticals? (5 min.)

Welcome investor! Scpharmaceuticals's management wants to use your money to grow the business. In return you get a share of Scpharmaceuticals.

What can you expect buying and holding a share of Scpharmaceuticals?

First you should know what it really means to hold a share of Scpharmaceuticals. And how you can make/lose money.

Speculation

The Price per Share of Scpharmaceuticals is $4.51. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Scpharmaceuticals.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Scpharmaceuticals, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.96. Based on the TTM, the Book Value Change Per Share is $-0.26 per quarter. Based on the YOY, the Book Value Change Per Share is $0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Scpharmaceuticals.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.36-7.9%-0.36-7.9%-0.26-5.7%-0.25-5.6%-0.25-5.5%
Usd Book Value Change Per Share-0.31-6.8%-0.26-5.8%0.112.5%-0.06-1.4%0.030.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.31-6.8%-0.26-5.8%0.112.5%-0.06-1.4%0.030.7%
Usd Price Per Share6.27-8.16-6.05-6.32-5.54-
Price to Earnings Ratio-4.40--5.86--5.97--6.51--5.64-
Price-to-Total Gains Ratio-20.33--652.57--16.82--144.70--121.45-
Price to Book Ratio6.53-5.72-4.89-3.98-3.16-
Price-to-Total Gains Ratio-20.33--652.57--16.82--144.70--121.45-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.51
Number of shares221
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.26-0.06
Usd Total Gains Per Share-0.26-0.06
Gains per Quarter (221 shares)-57.98-13.51
Gains per Year (221 shares)-231.93-54.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-232-2420-54-64
20-464-4740-108-118
30-696-7060-162-172
40-928-9380-216-226
50-1160-11700-271-280
60-1392-14020-325-334
70-1623-16340-379-388
80-1855-18661-433-442
90-2087-20981-487-496
100-2319-23301-541-550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.029.00.03.3%1.029.00.03.3%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%5.024.01.016.7%5.024.01.016.7%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.029.03.3%1.00.029.03.3%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%5.024.01.016.7%5.024.01.016.7%

Fundamentals of Scpharmaceuticals

About Scpharmaceuticals Inc

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-12 17:57:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Scpharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Scpharmaceuticals earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • A Net Profit Margin of -226.6% means that $-2.27 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Scpharmaceuticals Inc:

  • The MRQ is -226.6%. The company is making a huge loss. -2
  • The TTM is -531.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-226.6%TTM-531.1%+304.5%
TTM-531.1%YOY--531.1%
TTM-531.1%5Y-106.2%-424.9%
5Y-106.2%10Y-70.8%-35.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-226.6%-197.2%-29.4%
TTM-531.1%-210.4%-320.7%
YOY--279.3%+279.3%
5Y-106.2%-436.8%+330.6%
10Y-70.8%-599.3%+528.5%
1.1.2. Return on Assets

Shows how efficient Scpharmaceuticals is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • -14.6% Return on Assets means that Scpharmaceuticals generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Scpharmaceuticals Inc:

  • The MRQ is -14.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -13.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.6%TTM-13.0%-1.7%
TTM-13.0%YOY-14.5%+1.5%
TTM-13.0%5Y-10.6%-2.4%
5Y-10.6%10Y-29.1%+18.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.6%-13.6%-1.0%
TTM-13.0%-12.9%-0.1%
YOY-14.5%-11.9%-2.6%
5Y-10.6%-14.2%+3.6%
10Y-29.1%-16.2%-12.9%
1.1.3. Return on Equity

Shows how efficient Scpharmaceuticals is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • -37.1% Return on Equity means Scpharmaceuticals generated $-0.37 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Scpharmaceuticals Inc:

  • The MRQ is -37.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -17.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-37.1%TTM-17.2%-19.9%
TTM-17.2%YOY-18.6%+1.4%
TTM-17.2%5Y-14.1%-3.1%
5Y-14.1%10Y-11.7%-2.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-37.1%-17.0%-20.1%
TTM-17.2%-16.1%-1.1%
YOY-18.6%-15.4%-3.2%
5Y-14.1%-20.0%+5.9%
10Y-11.7%-21.1%+9.4%

1.2. Operating Efficiency of Scpharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Scpharmaceuticals is operating .

  • Measures how much profit Scpharmaceuticals makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • An Operating Margin of -250.3% means the company generated $-2.50  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Scpharmaceuticals Inc:

  • The MRQ is -250.3%. The company is operating very inefficient. -2
  • The TTM is -489.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-250.3%TTM-489.1%+238.8%
TTM-489.1%YOY--489.1%
TTM-489.1%5Y-97.8%-391.3%
5Y-97.8%10Y-65.2%-32.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-250.3%-286.1%+35.8%
TTM-489.1%-224.4%-264.7%
YOY--288.4%+288.4%
5Y-97.8%-475.2%+377.4%
10Y-65.2%-624.7%+559.5%
1.2.2. Operating Ratio

Measures how efficient Scpharmaceuticals is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.50 means that the operating costs are $3.50 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Scpharmaceuticals Inc:

  • The MRQ is 3.503. The company is inefficient in keeping operating costs low. -1
  • The TTM is 6.101. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.503TTM6.101-2.598
TTM6.101YOY-+6.101
TTM6.1015Y1.220+4.881
5Y1.22010Y0.813+0.407
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5032.997+0.506
TTM6.1013.247+2.854
YOY-3.766-3.766
5Y1.2205.675-4.455
10Y0.8137.857-7.044

1.3. Liquidity of Scpharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Scpharmaceuticals is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.08 means the company has $7.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Scpharmaceuticals Inc:

  • The MRQ is 7.076. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.524. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.076TTM12.524-5.448
TTM12.524YOY6.977+5.547
TTM12.5245Y10.607+1.917
5Y10.60710Y11.006-0.398
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0763.930+3.146
TTM12.5244.251+8.273
YOY6.9775.436+1.541
5Y10.6076.045+4.562
10Y11.0066.363+4.643
1.3.2. Quick Ratio

Measures if Scpharmaceuticals is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • A Quick Ratio of 8.35 means the company can pay off $8.35 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Scpharmaceuticals Inc:

  • The MRQ is 8.352. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.788. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.352TTM15.788-7.436
TTM15.788YOY8.902+6.886
TTM15.7885Y12.676+3.112
5Y12.67610Y11.762+0.913
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.3523.629+4.723
TTM15.7884.065+11.723
YOY8.9025.397+3.505
5Y12.6765.993+6.683
10Y11.7626.277+5.485

1.4. Solvency of Scpharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Scpharmaceuticals assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Scpharmaceuticals to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.61 means that Scpharmaceuticals assets are financed with 60.6% credit (debt) and the remaining percentage (100% - 60.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Scpharmaceuticals Inc:

  • The MRQ is 0.606. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.498. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.606TTM0.498+0.108
TTM0.498YOY0.343+0.155
TTM0.4985Y0.327+0.171
5Y0.32710Y0.382-0.055
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6060.332+0.274
TTM0.4980.334+0.164
YOY0.3430.268+0.075
5Y0.3270.366-0.039
10Y0.3820.390-0.008
1.4.2. Debt to Equity Ratio

Measures if Scpharmaceuticals is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • A Debt to Equity ratio of 153.9% means that company has $1.54 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Scpharmaceuticals Inc:

  • The MRQ is 1.539. The company is just able to pay all its debts with equity.
  • The TTM is 0.674. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ1.539TTM0.674+0.864
TTM0.674YOY0.353+0.321
TTM0.6745Y0.425+0.250
5Y0.42510Y0.336+0.088
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5390.381+1.158
TTM0.6740.390+0.284
YOY0.3530.334+0.019
5Y0.4250.434-0.009
10Y0.3360.466-0.130

2. Market Valuation of Scpharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Scpharmaceuticals generates.

  • Above 15 is considered overpriced but always compare Scpharmaceuticals to the Biotechnology industry mean.
  • A PE ratio of -4.40 means the investor is paying $-4.40 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Scpharmaceuticals Inc:

  • The EOD is -3.166. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.402. Based on the earnings, the company is expensive. -2
  • The TTM is -5.856. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.166MRQ-4.402+1.236
MRQ-4.402TTM-5.856+1.454
TTM-5.856YOY-5.969+0.112
TTM-5.8565Y-6.507+0.650
5Y-6.50710Y-5.640-0.867
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.166-2.315-0.851
MRQ-4.402-2.560-1.842
TTM-5.856-2.664-3.192
YOY-5.969-4.122-1.847
5Y-6.507-6.258-0.249
10Y-5.640-6.108+0.468
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Scpharmaceuticals Inc:

  • The EOD is -2.878. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -4.001. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.324. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.878MRQ-4.001+1.123
MRQ-4.001TTM-5.324+1.323
TTM-5.324YOY-6.403+1.079
TTM-5.3245Y-7.211+1.887
5Y-7.21110Y-6.548-0.662
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.878-3.067+0.189
MRQ-4.001-3.251-0.750
TTM-5.324-3.545-1.779
YOY-6.403-5.595-0.808
5Y-7.211-8.315+1.104
10Y-6.548-8.708+2.160
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Scpharmaceuticals is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.53 means the investor is paying $6.53 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Scpharmaceuticals Inc:

  • The EOD is 4.700. Based on the equity, the company is fair priced.
  • The MRQ is 6.534. Based on the equity, the company is overpriced. -1
  • The TTM is 5.722. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD4.700MRQ6.534-1.834
MRQ6.534TTM5.722+0.812
TTM5.722YOY4.892+0.830
TTM5.7225Y3.983+1.739
5Y3.98310Y3.163+0.820
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.7001.905+2.795
MRQ6.5342.111+4.423
TTM5.7222.095+3.627
YOY4.8922.836+2.056
5Y3.9833.443+0.540
10Y3.1633.794-0.631
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Scpharmaceuticals Inc.

3.1. Institutions holding Scpharmaceuticals Inc

Institutions are holding 75.867% of the shares of Scpharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Orbimed Advisors, LLC15.41980.6962555952800
2023-12-31Rubric Capital Management LP9.70760.4553350000078671328.9948
2023-12-31AIGH Capital Management, LLC8.6177.7064310679589978640.7695
2023-12-31BlackRock Inc5.16840.000318634391343197.7681
2023-12-31J. Goldman & Co LP3.89580.3563140460713167001497.8329
2023-12-31King Luther Capital Management Corp3.86510.042139352545715048.8213
2023-12-31Vanguard Group Inc3.79950.0002136988815087112.3764
2023-12-315AM Venture Management, LLC3.33011.9969120064700
2023-12-31Thrivent Financial For Lutherans2.91060.0143104940368140.6536
2023-12-31Walleye Trading Advisors, LLC2.32670.011283888041236096.6801
2023-12-31Worth Venture Partners, LLC2.13942.613877134423167942.9302
2023-12-31Tejara Capital Ltd2.10171.9901757771656357647.2055
2023-12-31StemPoint Capital LP1.57320.94885672115672110
2023-12-31State Street Corporation1.55410.0002560322-476493-45.9574
2023-12-31Geode Capital Management, LLC1.49150.0004537748259275.0656
2023-12-31Jefferies Financial Group Inc1.38680.0205500000-245550-32.9354
2023-12-31Millennium Management LLC0.98980.001356873-107686-23.1803
2023-12-31Northern Trust Corp0.74620.0003269036560.0208
2023-12-31Kennedy Capital Management Inc0.61850.0305223000-3604-1.5904
2023-12-31Morgan Stanley - Brokerage Accounts0.55080.0001198586-936993-82.5124
Total 72.192616.884826028603+3875617+14.9%

3.2. Funds holding Scpharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.35020.000384733400
2024-03-28iShares Russell 2000 ETF1.92730.00536948703360.0484
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.84620.001830508800
2024-01-31Fidelity Small Cap Index0.79940.005728822615730.5487
2024-03-28iShares Russell 2000 Growth ETF0.68570.0107247224-287-0.116
2023-12-31Kennedy Micro Cap0.61820.2948222877-3727-1.6447
2024-01-31Thrivent Small Cap Growth S0.50710.388718283923111.2801
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.50420.002618180018001
2024-01-31Thrivent Moderately Aggressive Allc0.48170.013317368512210.708
2024-01-31Thrivent Moderate Allocation0.40840.008214723610370.7093
2024-02-29Fidelity Extended Market Index0.35040.002126333-612-0.4821
2024-01-31Thrivent Moderately Agrsv Allocation A0.30.01351081807630.7103
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.29510.005510640000
2024-02-29Vanguard Russell 2000 ETF0.28690.006510344181888.5961
2023-09-30American Century Glbl Sm Cap Eq F USD0.28230.3114101767-6275-5.8079
2024-01-31Thrivent Small Cap Growth0.2630.3912948138600.9154
2023-12-31NT R2000 Growth Index Fund - NL0.23980.01478645700
2023-12-31Bridgeway Ultra-Small Company0.23580.61498500000
2023-12-31NT R2000 Index Fund - NL0.230.0072829221420.1715
2024-01-31Thrivent Aggressive Allocation S0.21730.0161783445520.7096
Total 11.8292.11444264836+7882+0.2%

3.3. Insider Transactions

Insiders are holding 6.589% of the shares of Scpharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-11-25Orbimed Advisors LlcBUY7623805.25
2022-10-105am Partners Iv, LlcSELL5624664.09
2022-10-065am Partners Iv, LlcSELL375345.02
2022-09-065am Partners Iv, LlcSELL266225.52
2022-04-115am Partners Iv, LlcSELL2700005
2021-12-03Jack A KhattarBUY50003.91
2021-12-03John H TuckerBUY100003.96

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Scpharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.308-0.262-15%0.111-379%-0.061-80%0.032-1064%
Book Value Per Share--0.9601.468-35%1.341-28%1.716-44%1.594-40%
Current Ratio--7.07612.524-44%6.977+1%10.607-33%11.006-36%
Debt To Asset Ratio--0.6060.498+22%0.343+77%0.327+85%0.382+59%
Debt To Equity Ratio--1.5390.674+128%0.353+336%0.425+262%0.336+357%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.356-0.3550%-0.255-28%-0.251-29%-0.249-30%
Free Cash Flow Per Share---0.392-0.385-2%-0.240-39%-0.243-38%-0.224-43%
Free Cash Flow To Equity Per Share---0.371-0.285-23%0.296-225%-0.021-94%0.064-679%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---17.051--------
Intrinsic Value_10Y_min---14.547--------
Intrinsic Value_1Y_max---1.177--------
Intrinsic Value_1Y_min---1.155--------
Intrinsic Value_3Y_max---3.941--------
Intrinsic Value_3Y_min---3.754--------
Intrinsic Value_5Y_max---7.193--------
Intrinsic Value_5Y_min---6.642--------
Market Cap162605344.000-50%243194214.120314076083.070-23%218038984.000+12%231982461.414+5%202463108.676+20%
Net Profit Margin---2.266-5.311+134%--100%-1.062-53%-0.708-69%
Operating Margin---2.503-4.891+95%--100%-0.978-61%-0.652-74%
Operating Ratio--3.5036.101-43%-+100%1.220+187%0.813+331%
Pb Ratio4.700-39%6.5345.722+14%4.892+34%3.983+64%3.163+107%
Pe Ratio-3.166+28%-4.402-5.856+33%-5.969+36%-6.507+48%-5.640+28%
Price Per Share4.510-39%6.2708.163-23%6.048+4%6.325-1%5.542+13%
Price To Free Cash Flow Ratio-2.878+28%-4.001-5.324+33%-6.403+60%-7.211+80%-6.548+64%
Price To Total Gains Ratio-14.625+28%-20.332-652.574+3110%-16.822-17%-144.704+612%-121.449+497%
Quick Ratio--8.35215.788-47%8.902-6%12.676-34%11.762-29%
Return On Assets---0.146-0.130-11%-0.145-1%-0.106-28%-0.291+99%
Return On Equity---0.371-0.172-54%-0.186-50%-0.141-62%-0.117-69%
Total Gains Per Share---0.308-0.262-15%0.111-378%-0.061-80%0.032-1063%
Usd Book Value--37218000.00056399500.000-34%48348250.000-23%62569750.000-41%57943366.667-36%
Usd Book Value Change Per Share---0.308-0.262-15%0.111-379%-0.061-80%0.032-1064%
Usd Book Value Per Share--0.9601.468-35%1.341-28%1.716-44%1.594-40%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.356-0.3550%-0.255-28%-0.251-29%-0.249-30%
Usd Free Cash Flow---15195000.000-14821000.000-2%-8651000.000-43%-8959150.000-41%-8190900.000-46%
Usd Free Cash Flow Per Share---0.392-0.385-2%-0.240-39%-0.243-38%-0.224-43%
Usd Free Cash Flow To Equity Per Share---0.371-0.285-23%0.296-225%-0.021-94%0.064-679%
Usd Market Cap162605344.000-50%243194214.120314076083.070-23%218038984.000+12%231982461.414+5%202463108.676+20%
Usd Price Per Share4.510-39%6.2708.163-23%6.048+4%6.325-1%5.542+13%
Usd Profit---13812000.000-14106750.000+2%-9571500.000-31%-9397550.000-32%-8568233.333-38%
Usd Revenue--6096000.0003398250.000+79%-+100%679650.000+797%453100.000+1245%
Usd Total Gains Per Share---0.308-0.262-15%0.111-378%-0.061-80%0.032-1063%
 EOD+3 -5MRQTTM+7 -26YOY+5 -305Y+5 -3010Y+6 -29

4.2. Fundamental Score

Let's check the fundamental score of Scpharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.166
Price to Book Ratio (EOD)Between0-14.700
Net Profit Margin (MRQ)Greater than0-2.266
Operating Margin (MRQ)Greater than0-2.503
Quick Ratio (MRQ)Greater than18.352
Current Ratio (MRQ)Greater than17.076
Debt to Asset Ratio (MRQ)Less than10.606
Debt to Equity Ratio (MRQ)Less than11.539
Return on Equity (MRQ)Greater than0.15-0.371
Return on Assets (MRQ)Greater than0.05-0.146
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Scpharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.989
Ma 20Greater thanMa 504.930
Ma 50Greater thanMa 1005.357
Ma 100Greater thanMa 2005.554
OpenGreater thanClose4.420
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets94,479
Total Liabilities57,261
Total Stockholder Equity37,218
 As reported
Total Liabilities 57,261
Total Stockholder Equity+ 37,218
Total Assets = 94,479

Assets

Total Assets94,479
Total Current Assets92,938
Long-term Assets1,541
Total Current Assets
Cash And Cash Equivalents 46,814
Short-term Investments 29,199
Net Receivables 4,489
Inventory 8,840
Other Current Assets 3,596
Total Current Assets  (as reported)92,938
Total Current Assets  (calculated)92,938
+/-0
Long-term Assets
Property Plant Equipment 1,459
Long-term Assets Other 82
Long-term Assets  (as reported)1,541
Long-term Assets  (calculated)1,541
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities13,134
Long-term Liabilities44,127
Total Stockholder Equity37,218
Total Current Liabilities
Short-term Debt 176
Accounts payable 4,001
Other Current Liabilities 8,957
Total Current Liabilities  (as reported)13,134
Total Current Liabilities  (calculated)13,134
+/-0
Long-term Liabilities
Long term Debt 38,811
Capital Lease Obligations 1,458
Long-term Liabilities Other 177
Long-term Liabilities  (as reported)44,127
Long-term Liabilities  (calculated)40,446
+/- 3,681
Total Stockholder Equity
Common Stock4
Retained Earnings -281,346
Accumulated Other Comprehensive Income -1
Other Stockholders Equity 318,561
Total Stockholder Equity (as reported)37,218
Total Stockholder Equity (calculated)37,218
+/-0
Other
Capital Stock4
Cash and Short Term Investments 76,013
Common Stock Shares Outstanding 38,787
Liabilities and Stockholders Equity 94,479
Net Debt -6,545
Net Invested Capital 76,029
Net Working Capital 79,804
Property Plant and Equipment Gross 1,520
Short Long Term Debt Total 40,269



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312015-12-31
> Total Assets 
1,846
39,772
39,329
39,329
33,934
122,048
113,652
105,009
98,819
93,755
87,587
83,459
86,666
77,283
80,488
123,919
116,960
109,048
100,293
93,615
87,531
79,037
68,893
59,162
48,400
124,195
127,371
114,171
106,101
94,479
94,479106,101114,171127,371124,19548,40059,16268,89379,03787,53193,615100,293109,048116,960123,91980,48877,28386,66683,45987,58793,75598,819105,009113,652122,04833,93439,32939,32939,7721,846
   > Total Current Assets 
1,818
39,740
39,105
39,105
33,538
119,883
111,568
102,965
96,831
91,893
85,811
81,773
84,887
75,647
79,073
122,536
115,688
107,826
99,066
92,492
86,470
78,275
68,226
57,855
47,169
123,308
126,667
113,574
104,339
92,938
92,938104,339113,574126,667123,30847,16957,85568,22678,27586,47092,49299,066107,826115,688122,53679,07375,64784,88781,77385,81191,89396,831102,965111,568119,88333,53839,10539,10539,7401,818
       Cash And Cash Equivalents 
1,573
39,282
37,899
37,899
31,435
118,298
109,280
100,768
95,299
89,660
83,560
79,467
83,744
72,806
75,339
78,860
44,278
105,277
75,837
74,969
79,323
74,268
51,630
41,178
41,289
71,061
75,453
71,350
35,042
46,814
46,81435,04271,35075,45371,06141,28941,17851,63074,26879,32374,96975,837105,27744,27878,86075,33972,80683,74479,46783,56089,66095,299100,768109,280118,29831,43537,89937,89939,2821,573
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
40,469
70,061
33,276
20,490
15,052
5,515
1,010
13,788
14,673
3,897
47,125
40,618
31,527
55,156
29,199
29,19955,15631,52740,61847,1253,89714,67313,7881,0105,51515,05220,49033,27670,06140,469000000000000000
       Net Receivables 
104
349
660
660
685
655
830
438
454
479
494
500
303
310
305
298
112
0
0
0
0
0
0
0
0
2,282
3,004
1,610
4,175
4,489
4,4894,1751,6103,0042,28200000000112298305310303500494479454438830655685660660349104
       Other Current Assets 
141
8
25
25
26
107
135
151
97
179
169
148
128
94
59
12
146
121
102
75
11
24
59
331
340
1,428
1,286
1,420
1,264
3,596
3,5961,2641,4201,2861,42834033159241175102121146125994128148169179971511351072625258141
   > Long-term Assets 
0
32
0
0
396
2,165
2,084
2,044
1,988
1,862
1,776
1,686
1,779
1,636
1,415
1,383
1,272
1,222
1,227
1,123
1,061
762
667
1,307
1,231
887
704
597
1,762
1,541
1,5411,7625977048871,2311,3076677621,0611,1231,2271,2221,2721,3831,4151,6361,7791,6861,7761,8621,9882,0442,0842,16539600320
       Property Plant Equipment 
23
26
35
35
209
1,976
1,895
1,854
1,797
1,670
1,581
1,492
1,400
1,306
1,211
1,112
1,012
908
802
693
590
479
384
842
739
620
514
408
1,574
1,459
1,4591,5744085146207398423844795906938029081,0121,1121,2111,3061,4001,4921,5811,6701,7971,8541,8951,97620935352623
       Long-term Assets Other 
0
6
0
0
187
189
189
190
191
192
195
194
379
330
204
271
260
314
425
430
471
283
283
283
310
267
190
189
188
82
821881891902673102832832834714304253142602712043303791941951921911901891891870060
> Total Liabilities 
2,013
76,846
14,416
14,416
14,280
16,051
15,708
16,417
15,429
15,011
17,189
19,990
28,780
25,918
25,384
25,860
27,145
26,878
24,778
24,572
24,421
22,567
19,500
18,705
17,290
51,762
51,564
50,744
56,955
57,261
57,26156,95550,74451,56451,76217,29018,70519,50022,56724,42124,57224,77826,87827,14525,86025,38425,91828,78019,99017,18915,01115,42916,41715,70816,05114,28014,41614,41676,8462,013
   > Total Current Liabilities 
2,005
3,736
4,684
4,684
4,832
5,211
5,800
7,463
7,430
6,673
10,096
13,532
8,104
5,237
4,663
5,929
7,197
9,321
9,648
11,888
14,205
14,846
14,175
15,540
17,176
7,416
7,735
6,635
10,951
13,134
13,13410,9516,6357,7357,41617,17615,54014,17514,84614,20511,8889,6489,3217,1975,9294,6635,2378,10413,53210,0966,6737,4307,4635,8005,2114,8324,6844,6843,7362,005
       Short-term Debt 
0
0
9,308
9,308
9,360
556
1,541
2,540
3,551
3,164
4,401
5,003
393
407
421
435
448
2,868
5,310
7,778
10,274
10,281
10,182
10,404
10,474
567
419
267
248
176
17624826741956710,47410,40410,18210,28110,2747,7785,3102,8684484354214073935,0034,4013,1643,5512,5401,5415569,3609,3089,30800
       Short Long Term Debt 
0
0
9,308
9,308
9,360
314
1,541
2,540
3,210
2,811
4,035
4,624
0
0
0
0
0
2,408
4,838
7,293
9,777
9,805
9,826
9,851
9,880
0
0
0
0
0
000009,8809,8519,8269,8059,7777,2934,8382,408000004,6244,0352,8113,2102,5401,5413149,3609,3089,30800
       Accounts payable 
684
1,546
871
871
1,010
1,591
1,519
2,358
1,667
587
221
1,419
542
1,142
652
770
839
1,666
753
531
447
544
445
982
996
1,518
1,626
1,182
3,370
4,001
4,0013,3701,1821,6261,5189969824455444475317531,6668397706521,1425421,4192215871,6672,3581,5191,5911,0108718711,546684
       Other Current Liabilities 
1,321
2,190
2
2
3,822
1
4
309
341
353
366
7,489
7,169
3,688
3,590
4,724
5,910
4,787
3,585
40
20
26
3,548
4,154
5,706
5,331
5,690
66
224
8,957
8,957224665,6905,3315,7064,1543,5482620403,5854,7875,9104,7243,5903,6887,1697,489366353341309413,822222,1901,321
   > Long-term Liabilities 
0
73,110
0
0
9,448
10,840
9,908
8,954
7,999
8,338
7,093
6,458
20,676
20,681
20,721
19,931
19,948
17,557
15,130
12,684
10,216
7,721
5,325
3,165
114
44,346
43,829
44,109
46,004
44,127
44,12746,00444,10943,82944,3461143,1655,3257,72110,21612,68415,13017,55719,94819,93120,72120,68120,6766,4587,0938,3387,9998,9549,90810,8409,4480073,1100
       Long term Debt Total 
0
0
0
0
0
0
8,222
7,331
6,421
6,826
5,649
5,086
18,842
18,915
18,996
19,076
19,170
16,858
14,515
12,156
9,777
7,354
4,913
2,463
0
36,794
37,252
0
0
0
00037,25236,79402,4634,9137,3549,77712,15614,51516,85819,17019,07618,99618,91518,8425,0865,6496,8266,4217,3318,222000000
       Capital Lease Obligations Min Short Term Debt
0
0
-9,308
-9,308
-9,360
-556
-1,541
-2,540
-3,551
-3,164
-2,780
-3,468
1,052
943
832
717
600
-1,928
-4,482
-7,064
-9,678
-9,805
-9,816
-9,580
-9,766
7
5
4
1,303
1,282
1,2821,303457-9,766-9,580-9,816-9,805-9,678-7,064-4,482-1,9286007178329431,052-3,468-2,780-3,164-3,551-2,540-1,541-556-9,360-9,308-9,30800
       Long-term Liabilities Other 
0
0
0
0
0
0
1,686
1,623
1,578
1,512
189
216
16
58
98
138
778
219
615
299
439
367
412
702
114
35
67
97
136
177
1771369767351147024123674392996152197781389858162161891,5121,5781,6231,686000000
       Deferred Long Term Liability 
0
7
0
0
0
151
0
0
0
0
0
0
766
765
795
0
0
0
0
0
0
0
0
0
0
7,517
6,510
0
0
0
0006,5107,517000000000079576576600000015100070
> Total Stockholder Equity
-18,240
-37,074
-37,074
-48,181
19,654
105,997
97,944
88,592
83,390
78,744
70,398
63,469
57,886
51,365
55,104
98,059
89,815
82,170
75,515
69,043
63,110
56,470
49,393
40,457
31,110
-226,536
-237,746
-251,900
49,146
37,218
37,21849,146-251,900-237,746-226,53631,11040,45749,39356,47063,11069,04375,51582,17089,81598,05955,10451,36557,88663,46970,39878,74483,39088,59297,944105,99719,654-48,181-37,074-37,074-18,240
   Common Stock
1
0
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
3
4
4
4
4
444433333333333222222222211101
   Retained Earnings -281,346-267,534-251,900-237,746-226,536-217,288-207,126-197,429-189,698-182,380-175,828-168,766-161,664-153,880-144,842-136,547-129,455-118,640-112,433-105,178-96,459-91,360-85,599-75,748-67,016-60,143-54,647-54,647-43,199-18,822
   Capital Surplus 
0
0
0
0
0
0
173,690
174,189
174,748
175,201
175,574
175,900
176,524
180,818
191,649
242,898
243,684
243,830
244,279
244,868
245,487
246,166
246,823
247,587
248,395
298,934
313,541
0
0
0
000313,541298,934248,395247,587246,823246,166245,487244,868244,279243,830243,684242,898191,649180,818176,524175,900175,574175,201174,748174,189173,690000000
   Treasury Stock000000000000000000000000000000
   Other Stockholders Equity 
0
6,134
0
0
79,813
173,037
174,038
174,619
175,245
175,801
176,246
176,661
177,377
180,920
191,759
243,017
243,684
243,830
244,279
244,868
245,487
246,166
246,823
247,587
248,395
-35
-12
2
316,678
318,561
318,561316,6782-12-35248,395247,587246,823246,166245,487244,868244,279243,830243,684243,017191,759180,920177,377176,661176,246175,801175,245174,619174,038173,03779,813006,1340



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue13,593
Cost of Revenue-3,811
Gross Profit9,7829,782
 
Operating Income (+$)
Gross Profit9,782
Operating Expense-65,178
Operating Income-55,396-55,396
 
Operating Expense (+$)
Research Development11,809
Selling General Administrative53,369
Selling And Marketing Expenses0
Operating Expense65,17865,178
 
Net Interest Income (+$)
Interest Income4,829
Interest Expense-8,123
Other Finance Cost-133
Net Interest Income-3,161
 
Pretax Income (+$)
Operating Income-55,396
Net Interest Income-3,161
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-54,810-55,982
EBIT - interestExpense = -63,519
-54,810
-46,687
Interest Expense8,123
Earnings Before Interest and Taxes (EBIT)-55,396-46,687
Earnings Before Interest and Taxes (EBITDA)-54,770
 
After tax Income (+$)
Income Before Tax-54,810
Tax Provision-0
Net Income From Continuing Ops-50,246-54,810
Net Income-54,810
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses68,989
Total Other Income/Expenses Net5863,161
 

Technical Analysis of Scpharmaceuticals
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Scpharmaceuticals. The general trend of Scpharmaceuticals is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Scpharmaceuticals's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Scpharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.63 < 4.65 < 4.74.

The bearish price targets are: 4.02 > 3.68.

Tweet this
Scpharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Scpharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Scpharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Scpharmaceuticals Inc. The current macd is -0.21051631.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Scpharmaceuticals price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Scpharmaceuticals. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Scpharmaceuticals price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Scpharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartScpharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Scpharmaceuticals Inc. The current adx is 17.74.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Scpharmaceuticals shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Scpharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Scpharmaceuticals Inc. The current sar is 5.27892669.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Scpharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Scpharmaceuticals Inc. The current rsi is 37.99. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Scpharmaceuticals Inc Daily Relative Strength Index (RSI) ChartScpharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Scpharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Scpharmaceuticals price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Scpharmaceuticals Inc Daily Stochastic Oscillator ChartScpharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Scpharmaceuticals Inc. The current cci is -210.28188757.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Scpharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartScpharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Scpharmaceuticals Inc. The current cmo is -28.98848358.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Scpharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartScpharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Scpharmaceuticals Inc. The current willr is -75.92592593.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Scpharmaceuticals is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Scpharmaceuticals Inc Daily Williams %R ChartScpharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Scpharmaceuticals Inc.

Scpharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Scpharmaceuticals Inc. The current atr is 0.30429613.

Scpharmaceuticals Inc Daily Average True Range (ATR) ChartScpharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Scpharmaceuticals Inc. The current obv is -15,247,901.

Scpharmaceuticals Inc Daily On-Balance Volume (OBV) ChartScpharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Scpharmaceuticals Inc. The current mfi is 28.83.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Scpharmaceuticals Inc Daily Money Flow Index (MFI) ChartScpharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Scpharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Scpharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Scpharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5037.989
Ma 20Greater thanMa 504.930
Ma 50Greater thanMa 1005.357
Ma 100Greater thanMa 2005.554
OpenGreater thanClose4.420
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Scpharmaceuticals with someone you think should read this too:
  • Are you bullish or bearish on Scpharmaceuticals? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Scpharmaceuticals? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Scpharmaceuticals Inc

I send you an email if I find something interesting about Scpharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Scpharmaceuticals Inc.

Receive notifications about Scpharmaceuticals Inc in your mailbox!